secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2024-06-20T23:59:59+00:00
Accession:  0001104659-24-073484
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Brainstorm Cell Therapeutics appoints Hartoun Hartounian as EVP and COO, effective June 24, 2024
--------------------------------------------------------------------------------

- Hartoun Hartounian appointed EVP and COO, effective June 24, 2024.
- Base salary $450k/year; option for 60k shares and 30k restricted stock grant.
- Eligible for annual cash bonus up to 35% of base salary and $10k signing bonus.
- Previously founded BioCentriq, a CDMO acquired for $73M by GC Holdings.
- Appointment supports operational readiness for NurOwn® Phase 3b ALS study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465924073484/0001104659-24-073484-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465924073484/tm2417625d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-073484

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer